Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
50-21-5
Molecular formula
C3H6O3
Molecular weight
90.08 g/mol
Drug class
Alpha-hydroxy acidTopical humectant and keratolytic agent
Mechanism of action
Lactic acid is an alpha-hydroxy acid. In topical formulations it may act as a humectant and reduce corneocyte cohesion; the precise mechanism of these skin effects is not fully established.
Indications / reported uses
Topical treatment of ichthyosis vulgaris and xerosis in ammonium-lactate formulations
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information
Drug class, mechanism of action and general use cases
Drug class
Vitamin C; Vitamin D; Vitamin B12; Calcium
Mechanism of action
Acidifying Activity
General use cases
Dermatitis
Facial Dermatoses
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Lactic Acid Environmental Risk Assessment (ERA) (the Lactic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.